STANFORD UNIVERSITY
Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome [revised IND and clinical protocol to be submitted to FDA by 10/11/2021]
Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome [revised IND and clinical protocol to be submitted to FDA by 10/11/2021] is a funding opportunity from STANFORD UNIVERSITY, up to 669615, closing July 31, 2026.
Jul 31, 2026
(0d left)Overview
Project Summary We propose a novel regulatory T (Treg) cell therapy to treat IPEX syndrome, a rare autoimmune monogenic disease. IPEX is a life-threatening disease caused by loss-of-function FOXP3 mutations leading to dysfunctional Treg cells. The only current curative treatment for IPEX is allogeneic hematopoietic…